Retatrutide is not available here as a medicine. A 23 September 2026 portal search found no registered retatrutide product, and FDA Philippines warned the public against an unregistered retatrutide 30 mg vial (FDA Advisory No. 2026-1265, 26 September 2026). No regulator has approved it. Lilly plans a US filing in Q1 2027. What is sold here is research material.
Compound guide · Retatrutide
Retatrutide in the Philippines: status, trials and sourcing
Where retatrutide stands in the Philippines: what it is, what the phase 3 trials found and reported as side effects, its legal and regulatory position, and the batch report from our partner and supplier.
Video transcript
Searching for retatrutide in the Philippines? Here is the short answer, checked September 2026. Retatrutide is an investigational peptide from Eli Lilly that activates three hormone receptors: GLP-1, GIP and glucagon. It is not registered with FDA Philippines, and no regulator anywhere has approved it. No pharmacy here sells it, and no pharmaceutical version exists, so pharmacy grade claims are mislabelled. In TRIUMPH-1, a phase 3 trial of 2,339 adults without diabetes, body weight fell 28.3% at 80 weeks on the highest-dose arm, against 2.2% on placebo. The most common side effects were nausea, diarrhoea and constipation. Nausea was reported in 28.6% to 42.4% of participants. 11.3% on the highest-dose arm stopped because of side effects, against 4.9% on placebo. Dysesthesia, a change in skin sensation, appeared in every phase 3 trial. What is sold here is research material: not approved for human use, and sold for research only. Our partner and supplier, Primara Labs, lists a retatrutide vial at [₱3,390 for the 20 mg vial], or [₱2,076] each in a 10 pack. That is about [₱170] per mg, or [₱104] in a 10 pack. Retatrutide batch RETA-4728-A was tested by Janoshik for bacterial endotoxin. Batch reports are published at primaralabs.com/coa as they are issued. Every vial order includes bacteriostatic water, insulin syringes and alcohol pads. Metro Manila orders before noon arrive the same day, provinces ship by J&T, and there is a 60-day money-back guarantee. Read the full guide on Philippines Peptides, then see retatrutide at Primara Labs and order on WhatsApp. [Figures in square brackets corrected on 3 November 2026 from Primara's current catalogue: the narration gives the price of the 15 mg retatrutide vial, retired on 12 October 2026.]
Short answer
What retatrutide is
Retatrutide (LY3437943) is an investigational peptide from Eli Lilly that activates three hormone receptors: GLP-1, the target of semaglutide; GIP, the second target of tirzepatide; and glucagon. It is being studied for obesity and type 2 diabetes. The mechanism, half-life and each safety topic are covered on the retatrutide compound page.
No pharmaceutical retatrutide exists anywhere. A product described as "pharmacy grade" or "prescription" retatrutide is mislabelled, because no regulator has approved one.
What the trials found
In TRIUMPH-1, an 80-week phase 3 trial of 2,339 adults with obesity, or overweight with at least one weight-related condition, without diabetes, body weight fell by 19%, 25.9% and 28.3% on the 4 mg, 9 mg and 12 mg arms, against 2.2% on placebo. Source · Registry
| Trial and population | n | Weeks | Change by arm | Comparator | Source |
|---|---|---|---|---|---|
| TRIUMPH-1 · Phase 3Adults with obesity, or overweight with at least one weight-related condition, without diabetes | 2,339 | 80 | 4 mg −19%9 mg −25.9%12 mg −28.3% | Placebo −2.2% | Source · Registry |
| TRIUMPH-2 · Phase 3Adults with type 2 diabetes and obesity or overweight | 1,152 | 80 | 4 mg −12.7%9 mg −19.1%12 mg −20.8% | Placebo −4% | Source · Registry |
| TRIUMPH-3 · Phase 3Adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes | 1,949 | 80 | 9 mg −21.6%12 mg −22.6% | Placebo −3.2% | Source · Registry |
| TRIUMPH-4 · Phase 3Adults with obesity or overweight and knee osteoarthritis, without diabetes | 445 | 68 | 9 mg −26.4%12 mg −28.7% | Placebo −2.1% | Source · Registry |
| Retatrutide phase 2 (Jastreboff) · Phase 2Adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition | 338 | 48 | 1 mg −8.7%4 mg (pooled) −17.1%8 mg (pooled) −22.8%12 mg −24.2% | Placebo −2.1% | Source · Registry |
| Trial | Highest-dose arm | Comparator |
|---|---|---|
| TRIUMPH-1 | 12 mg −28.3% | Placebo −2.2% |
| TRIUMPH-2 | 12 mg −20.8% | Placebo −4% |
| TRIUMPH-3 | 12 mg −22.6% | Placebo −3.2% |
| TRIUMPH-4 | 12 mg −28.7% | Placebo −2.1% |
| Retatrutide phase 2 (Jastreboff) | 12 mg −24.2% | Placebo −2.1% |
Each pair is one trial: the highest-dose arm (dark) and the comparator (light). Full results and arms are in the table above.
The same figures as sentences
- In TRIUMPH-2, an 80-week phase 3 trial of 1,152 adults with type 2 diabetes and obesity or overweight, body weight fell by 12.7%, 19.1% and 20.8% on the 4 mg, 9 mg and 12 mg arms, against 4% on placebo. Source · Registry
- In TRIUMPH-3, an 80-week phase 3 trial of 1,949 adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes, body weight fell by 21.6% and 22.6% on the 9 mg and 12 mg arms, against 3.2% on placebo. Source · Registry
- In TRIUMPH-4, a 68-week phase 3 trial of 445 adults with obesity or overweight and knee osteoarthritis, without diabetes, body weight fell by 26.4% and 28.7% on the 9 mg and 12 mg arms, against 2.1% on placebo. Source · Registry
- In Retatrutide phase 2 (Jastreboff), a 48-week phase 2 trial of 338 adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition, body weight fell by 8.7%, 17.1%, 22.8% and 24.2% on the 1 mg, 4 mg (pooled), 8 mg (pooled) and 12 mg arms, against 2.1% on placebo. Source · Registry
Trials of Retatrutide still running
6 registered trials: TRIUMPH-5, TRIUMPH-6, TRIUMPH-7, TRIUMPH-8, TRIUMPH-9, TRIUMPH-OUTCOMES
- TRIUMPH-5, phase 3, in adults who have obesity. Measuring: compared with tirzepatide.
- TRIUMPH-6, phase 3, in adults with obesity. Measuring: maintenance of weight reduction.
- TRIUMPH-7, phase 3, in adults with obesity or overweight and chronic low back pain.
- TRIUMPH-8, phase 3, in adults with obesity or overweight.
- TRIUMPH-9, phase 3, in adults without type 2 diabetes who have obesity or overweight.
- TRIUMPH-OUTCOMES, phase 3, in adults living with obesity. Measuring: cardiovascular and kidney outcomes.
Findings, evidence levels and sources are from the Research Desk datasets published by Primara Labs, our partner and supplier, synced 23 September 2026 and summarised here in this site’s own words.
Side effects reported
Full side-effect table by trial
TRIUMPH-1, an 80-week phase 3 trial of 2,339 adults with obesity, or overweight with at least one weight-related condition, without diabetes, reported:
| Adverse event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Discontinuation for adverse events | 4.1% | 6.9% | 11.3% | 4.9% |
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhoea | 25.2% | 34.1% | 32% | 13.5% |
| Constipation | 23.8% | 25.9% | 26.1% | 10.9% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
| Dysesthesia | 5.1% | 12.3% | 12.5% | 0.9% |
| Urinary tract infection | 7.5% | 8.8% | 8.4% | 5.3% |
The same figures as sentences
- Discontinuation for adverse events: 4.1%, 6.9% and 11.3% on the 4, 9 and 12 mg arms, against 4.9% on placebo.
- Nausea: 28.6%, 38.4% and 42.4% on the 4, 9 and 12 mg arms, against 14.8% on placebo.
- Diarrhoea: 25.2%, 34.1% and 32% on the 4, 9 and 12 mg arms, against 13.5% on placebo.
- Constipation: 23.8%, 25.9% and 26.1% on the 4, 9 and 12 mg arms, against 10.9% on placebo.
- Vomiting: 10.6%, 22.8% and 25.3% on the 4, 9 and 12 mg arms, against 4.8% on placebo.
- Dysesthesia: 5.1%, 12.3% and 12.5% on the 4, 9 and 12 mg arms, against 0.9% on placebo.
- Urinary tract infection: 7.5%, 8.8% and 8.4% on the 4, 9 and 12 mg arms, against 5.3% on placebo.
TRIUMPH-2, an 80-week phase 3 trial of 1,152 adults with type 2 diabetes and obesity or overweight, reported:
| Adverse event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Discontinuation for adverse events | 3.8% | 11.6% | 7.7% | 4.9% |
| Diarrhoea | 27.4% | 33.5% | 33.6% | 13.2% |
| Nausea | 13.7% | 20.8% | 28% | 8% |
| Constipation | 14% | 16.2% | 16.8% | 9.4% |
| Decreased appetite | 5.8% | 12.3% | 17.1% | 4.5% |
| Vomiting | 5.5% | 10.2% | 15.7% | 4.2% |
| Dysesthesia | 4.5% | 5.6% | 7.3% | 0.7% |
| Urinary tract infection | 3.8% | 6.3% | 8% | 6.6% |
The same figures as sentences
- Discontinuation for adverse events: 3.8%, 11.6% and 7.7% on the 4, 9 and 12 mg arms, against 4.9% on placebo.
- Diarrhoea: 27.4%, 33.5% and 33.6% on the 4, 9 and 12 mg arms, against 13.2% on placebo.
- Nausea: 13.7%, 20.8% and 28% on the 4, 9 and 12 mg arms, against 8% on placebo.
- Constipation: 14%, 16.2% and 16.8% on the 4, 9 and 12 mg arms, against 9.4% on placebo.
- Decreased appetite: 5.8%, 12.3% and 17.1% on the 4, 9 and 12 mg arms, against 4.5% on placebo.
- Vomiting: 5.5%, 10.2% and 15.7% on the 4, 9 and 12 mg arms, against 4.2% on placebo.
- Dysesthesia: 4.5%, 5.6% and 7.3% on the 4, 9 and 12 mg arms, against 0.7% on placebo.
- Urinary tract infection: 3.8%, 6.3% and 8% on the 4, 9 and 12 mg arms, against 6.6% on placebo.
TRIUMPH-3, an 80-week phase 3 trial of 1,949 adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes, reported:
| Adverse event | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Discontinuation for adverse events | 9.8% | 13.5% | 4.8% |
| Diarrhoea | 30.1% | 24.4% | 8.7% |
| Nausea | 21.7% | 22.4% | 5.8% |
| Constipation | 18% | 15.7% | 7.1% |
| Decreased appetite | 13.5% | 14.5% | 3% |
| Dysesthesia | 6.4% | 6.4% | 1.3% |
| Urinary tract infection | 6.1% | 7% | 5.3% |
The same figures as sentences
- Discontinuation for adverse events: 9.8% and 13.5% on the 9 and 12 mg arms, against 4.8% on placebo.
- Diarrhoea: 30.1% and 24.4% on the 9 and 12 mg arms, against 8.7% on placebo.
- Nausea: 21.7% and 22.4% on the 9 and 12 mg arms, against 5.8% on placebo.
- Constipation: 18% and 15.7% on the 9 and 12 mg arms, against 7.1% on placebo.
- Decreased appetite: 13.5% and 14.5% on the 9 and 12 mg arms, against 3% on placebo.
- Dysesthesia: 6.4% and 6.4% on the 9 and 12 mg arms, against 1.3% on placebo.
- Urinary tract infection: 6.1% and 7% on the 9 and 12 mg arms, against 5.3% on placebo.
TRIUMPH-4, a 68-week phase 3 trial of 445 adults with obesity or overweight and knee osteoarthritis, without diabetes, reported:
| Adverse event | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Discontinuation for adverse events | 12.2% | 18.2% | 4% |
| Nausea | 38.1% | 43.2% | 10.7% |
| Diarrhoea | 34.7% | 33.1% | 13.4% |
| Constipation | 21.8% | 25% | 8.7% |
| Vomiting | 20.4% | 20.9% | 0% |
| Decreased appetite | 19% | 18.2% | 9.4% |
| Dysesthesia | 8.8% | 20.9% | 0.7% |
The same figures as sentences
- Discontinuation for adverse events: 12.2% and 18.2% on the 9 and 12 mg arms, against 4% on placebo.
- Nausea: 38.1% and 43.2% on the 9 and 12 mg arms, against 10.7% on placebo.
- Diarrhoea: 34.7% and 33.1% on the 9 and 12 mg arms, against 13.4% on placebo.
- Constipation: 21.8% and 25% on the 9 and 12 mg arms, against 8.7% on placebo.
- Vomiting: 20.4% and 20.9% on the 9 and 12 mg arms, against 0% on placebo.
- Decreased appetite: 19% and 18.2% on the 9 and 12 mg arms, against 9.4% on placebo.
- Dysesthesia: 8.8% and 20.9% on the 9 and 12 mg arms, against 0.7% on placebo.
Status in the Philippines
A search of the FDA Philippines verification portal on 23 September 2026 returned no registered retatrutide product. The same search found none for BPC-157 Philippines or selank, two other compounds sold here as research vials. Under RA 9711, anything intended to affect the structure or a function of the body is a drug, and a drug must be registered before it is imported, sold or distributed. What registration means is on the FDA registration page.
In FDA Advisory No. 2026-1265, 26 September 2026, the FDA warned the public against buying or using the unregistered drug product Retatrutide 30 mg lyophilized powder for injection, which has no Certificate of Product Registration. In FDA Advisory No. 2026-1392, 6 October 2026, the FDA warned the public against buying or using the unregistered drug product Retatrutide 30 mg lyophilized powder for injection, which has no Certificate of Product Registration. On 4 September 2026 the regulator warned the public against two unregistered tirzepatide vials sold with bacteriostatic water, a vial-and-water format also used for research peptides. The full list is on the advisories timeline.
This is general information, not legal advice.
Regulatory timeline
- 26 June 2023: Retatrutide phase 2 (Jastreboff) (phase 2) read out.
- 11 December 2025: TRIUMPH-4 (phase 3) read out.
- 21 May 2026: TRIUMPH-1 (phase 3) read out.
- 23 July 2026: TRIUMPH-2 (phase 3) read out.
- 23 July 2026: TRIUMPH-3 (phase 3) read out.
- Q1 2027: Lilly plans a US Biologics License Application submission in Q1 2027, per its release of 23 July 2026.
Still running: TRIUMPH-5, TRIUMPH-6, TRIUMPH-7, TRIUMPH-8, TRIUMPH-9, TRIUMPH-OUTCOMES. The status by regulator is on the regulatory status page.
Batch report
Retatrutide batch report from our partner and supplier
Janoshik-tested for bacterial endotoxin, batch RETA-4728-A
Retatrutide. Laboratory: Janoshik. Test: Bacterial endotoxin (LAL). Analysed 21 September 2026. Result as printed: 6.066 EU per vial.
This report covers bacterial endotoxin only. It does not establish identity or purity.
Task 234146 · Verification key H2KI86I8GWB4 · verify at verify.janoshik.com
From the batch-report dataset Primara Labs publishes, updated 23 September 2026. The store’s own list: Primara Labs batch reports.
Sourcing
Retatrutide sold in the Philippines is research material, not a registered medicine. No prescriber, pharmacist or regulator stands behind it, and every decision after delivery sits with the buyer. The questions worth asking any seller are on the supply index.
FAQ
Is retatrutide available in the Philippines?
Not as a medicine. A search of the FDA Philippines verification portal on 23 September 2026 returned no registered retatrutide product, and no regulator anywhere has approved one, so no Philippine pharmacy or hospital sells it. FDA Philippines has warned the public against buying or using an unregistered retatrutide 30 mg vial (FDA Advisory No. 2026-1265, 26 September 2026). What is sold is research material, labelled for research use.
Is retatrutide legal in the Philippines?
Retatrutide is not registered with FDA Philippines. Under RA 9711 a drug must be registered before it is imported, sold or distributed, and FDA Philippines has warned the public against unregistered GLP-1 products such as tirzepatide vials sold with bacteriostatic water. This is general information, not legal advice.
When will retatrutide be approved?
No approval date exists. Sponsor plans a US Biologics License Application submission in Q1 2027, according to Lilly's release of 23 July 2026. A US submission is not an approval, and no Philippine filing has been announced.
What did the retatrutide trials find?
In TRIUMPH-1, a phase 3 trial of 2,339 adults with obesity or overweight without diabetes, body weight fell by 28.3% at 80 weeks on the highest-dose arm, against 2.2% on placebo. The most common adverse events were gastrointestinal, and dysesthesia, a change in skin sensation, was reported in every phase 3 trial.
What has Eli Lilly said about research-use retatrutide?
On 12 August 2026 Lilly stated that no retatrutide medicine is approved anywhere and said it has sued US sellers that label retatrutide research-use only while intending it for human use. The statement does not mention the Philippines.